Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc. - Common Stock (NQ:COSM)

0.4874 +0.0416 (+9.33%)
Streaming Delayed Price Updated: 12:53 PM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cosmos Health Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Announces Launch Of Food Supplement Brand In Albania: Retail Sentiment Improves ↗
The company said that the launch is in partnership with Tirana-based pharmaceutical company Pharma Cell, which will serve as the distributor in the country. 
Via Stocktwits
Topics Economy Government
News headline image
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
Via ACCESS Newswire
News headline image
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency ↗
Virax Biolabs supports HHS's focus on vaccine efficacy transparency, offering technology to assess immune responses and collaborate with developers to improve vaccine research. 
Via Benzinga
News headline image
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
Via ACCESS Newswire
News headline image
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Via ACCESS Newswire
News headline image
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
Via ACCESS Newswire
News headline image
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
Via ACCESS Newswire
News headline image
Cosmos Health Pockets 10-Year Manufacturing Deal With Provident Pharmaceuticals ↗
Cosmos Health announced a ten-year contract with Provident Pharmaceuticals for production of four key drugs. 
Via Benzinga
News headline image
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
Via ACCESS Newswire
News headline image
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
Via ACCESS Newswire
News headline image
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
Via ACCESS Newswire
News headline image
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
Via ACCESS Newswire
News headline image
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
Via ACCESS Newswire
News headline image
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
Via ACCESS Newswire
News headline image
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
Via ACCESS Newswire
News headline image
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
Via ACCESS Newswire
News headline image
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
Via ACCESSWIRE
News headline image
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
Via ACCESSWIRE
News headline image
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
Via ACCESSWIRE
News headline image
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price
Via ACCESSWIRE
News headline image
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
Via ACCESSWIRE
News headline image
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
Via ACCESSWIRE
News headline image
Cosmos Health Issues Letter to Shareholders
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.